Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Glycemic Effects of Honey
Glycemic Effects of Honey
Status: Enrolling
Updated:  12/31/1969
Grand Forks Human Nutrition Research Center
1313
mi
from 02139
Grand Forks, ND
Glycemic Effects of Honey
Glycemic Effects of Honey
Status: Enrolling
Updated: 12/31/1969
Grand Forks Human Nutrition Research Center
1313
mi
from 02139
Grand Forks, ND
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
ClinTriCo
2287
mi
from 02139
Phoenix, AZ
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
ClinTriCo
2287
mi
from 02139
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles UCLA Tiverton
2598
mi
from 02139
Los Angeles, CA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles UCLA Tiverton
2598
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Medical Center LA Biomed
2599
mi
from 02139
Torrance, CA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Medical Center LA Biomed
2599
mi
from 02139
Torrance, CA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine/Winship Cancer Institute G2304 - C2301
929
mi
from 02139
Atlanta, GA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine/Winship Cancer Institute G2304 - C2301
929
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Pituitary Center, Division of Endocrinology SC
357
mi
from 02139
Baltimore, MD
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Pituitary Center, Division of Endocrinology SC
357
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center SC-2
641
mi
from 02139
Ann Arbor, MI
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center SC-2
641
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine Mt. Sinai Medical Center
182
mi
from 02139
New York, NY
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine Mt. Sinai Medical Center
182
mi
from 02139
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Sciences University DeptofOregonHealth&Sciences(2)
2531
mi
from 02139
Portland, OR
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Sciences University DeptofOregonHealth&Sciences(2)
2531
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania - Clinical Studies Unit Unniv SC
268
mi
from 02139
Philadelphia, PA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania - Clinical Studies Unit Unniv SC
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center CSOM230G2304
939
mi
from 02139
Nashville, TN
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center CSOM230G2304
939
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center Swedish
2483
mi
from 02139
Seattle, WA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center Swedish
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin MCW 2
853
mi
from 02139
Milwaukee, WI
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin MCW 2
853
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
5378
mi
from 02139
Buenos Aires,
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
5378
mi
from 02139
Buenos Aires,
Click here to add this to my saved trials
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated:  12/31/1969
Michael E. DeBakey VA Medical Center, Houston, TX
1606
mi
from 02139
Houston, TX
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated: 12/31/1969
Michael E. DeBakey VA Medical Center, Houston, TX
1606
mi
from 02139
Houston, TX
Click here to add this to my saved trials
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated:  12/31/1969
New Mexico VA Health Care System, Albuquerque, NM
1965
mi
from 02139
Albuquerque, NM
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated: 12/31/1969
New Mexico VA Health Care System, Albuquerque, NM
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
Effect of Dietary Glycemic Index on Beta-cell Function
Effect of Dietary Glycemic Index on Beta-cell Function
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
2483
mi
from 02139
Seattle, WA
Effect of Dietary Glycemic Index on Beta-cell Function
Effect of Dietary Glycemic Index on Beta-cell Function
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
268
mi
from 02139
Philadelphia, PA
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Mifepristone for Metabolic Syndrome
Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Mifepristone for Metabolic Syndrome
Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
490
mi
from 02139
Charlottesville, VA
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
490
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
490
mi
from 02139
Charlottesville, VA
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
490
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Caveolin-1 and Vascular Dysfunction
Caveolin-1 and Vascular Dysfunction
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Caveolin-1 and Vascular Dysfunction
Caveolin-1 and Vascular Dysfunction
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
490
mi
from 02139
Charlottesville, VA
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
490
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
490
mi
from 02139
Charlottesville, VA
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
490
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
356
mi
from 02139
Baltimore, MD
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
356
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
1605
mi
from 02139
Houston, TX
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Status: Enrolling
Updated:  12/31/1969
Diabetes Division, UTHSCSA
1763
mi
from 02139
San Antonio, TX
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Status: Enrolling
Updated: 12/31/1969
Diabetes Division, UTHSCSA
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)
Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)
Status: Enrolling
Updated:  12/31/1969
Clinical Nutrition Research Center
846
mi
from 02139
Chicago, IL
Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)
Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)
Status: Enrolling
Updated: 12/31/1969
Clinical Nutrition Research Center
846
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Status: Enrolling
Updated:  12/31/1969
VCU Medical Center
472
mi
from 02139
Richmond, VA
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Status: Enrolling
Updated: 12/31/1969
VCU Medical Center
472
mi
from 02139
Richmond, VA
Click here to add this to my saved trials
Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance
Translational Diabetes Prevention in GDM
Status: Enrolling
Updated:  12/31/1969
Division of Research Northern California
2682
mi
from 02139
Oakland, CA
Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance
Translational Diabetes Prevention in GDM
Status: Enrolling
Updated: 12/31/1969
Division of Research Northern California
2682
mi
from 02139
Oakland, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
1049
mi
from 02139
Birmingham, AL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
1049
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1052
mi
from 02139
Birmingham, AL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1052
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
1256
mi
from 02139
Little Rock, AR
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
1256
mi
from 02139
Little Rock, AR
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Southern California Permanente Medical Group
2588
mi
from 02139
Downey, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Southern California Permanente Medical Group
2588
mi
from 02139
Downey, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Miller Children's Hospital
2593
mi
from 02139
Long Beach, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Miller Children's Hospital
2593
mi
from 02139
Long Beach, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
2588
mi
from 02139
Los Angeles, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Central California
2589
mi
from 02139
Madera, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Central California
2589
mi
from 02139
Madera, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
2577
mi
from 02139
Orange, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
2577
mi
from 02139
Orange, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rady Children's Hospital - San Diego
2573
mi
from 02139
San Diego, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital - San Diego
2573
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
1763
mi
from 02139
Denver, CO
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
1763
mi
from 02139
Denver, CO
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Medical Center
91
mi
from 02139
Hartford, CT
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Medical Center
91
mi
from 02139
Hartford, CT
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Alfred I. duPont Hospital for Children
292
mi
from 02139
Wilmington, DE
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Alfred I. duPont Hospital for Children
292
mi
from 02139
Wilmington, DE
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
392
mi
from 02139
Washington,
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
392
mi
from 02139
Washington,
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
1254
mi
from 02139
Fort Myers, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
1254
mi
from 02139
Fort Myers, FL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Orlando
1115
mi
from 02139
Orlando, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Orlando
1115
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Pensacola
1211
mi
from 02139
Pensacola, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Pensacola
1211
mi
from 02139
Pensacola, FL
Click here to add this to my saved trials